Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Rheum Dis Clin North Am. 2025 Feb;51(1):75-92. doi: 10.1016/j.rdc.2024.08.005. Epub 2024 Oct 15.
This narrative review summarizes current evidence on the risk of systemic autoimmune rheumatic disease (SARD) flare following coronavirus disease 2019 vaccination. The authors detail key studies in the literature employing diverse methodologies, including cross-sectional surveys, prospective and retrospective cohorts, case-crossover designs, self-controlled case series, and systematic reviews. Data are reassuring, suggesting that vaccination is unlikely to increase the risk of flares across a range of SARD. When postvaccination flares do occur, individuals with high disease activity and frequent flares at baseline may be at higher risk. Rheumatologists may consider discussing these findings with patients during collaborative conversations about risks and benefits of vaccination.
这篇叙述性评论总结了目前关于 COVID-19 疫苗接种后系统性自身免疫性风湿病 (SARD) 发作风险的证据。作者详细介绍了文献中的关键研究，这些研究采用了多种方法，包括横断面调查、前瞻性和回顾性队列研究、病例交叉设计、自身对照病例系列研究和系统评价。数据令人安心，表明疫苗接种不太可能增加一系列 SARD 发作的风险。当接种疫苗后确实出现发作时，基线时疾病活动度高且频繁发作的患者可能面临更高的风险。风湿病医生可以在关于疫苗接种风险和益处的协作对话中与患者讨论这些发现。
